Cerevel Therapeutics (CERE) News Today

California State Teachers Retirement System increased its holdings in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 63.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 122,437 share

Price T Rowe Associates Inc. MD trimmed its holdings in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 53.5% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 335,357 shares of the biotechnology company's stock after selling 385,6

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock traders acquired 15,827 call options on the company. This is an increase of approximately 633% compared to the typical volume of 2,158 call options.

Cerevel Therapeutics (NASDAQ:CERE) Hits New 12-Month High at $44.66

Vanguard Group Inc. lifted its position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 1.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,463,911 shares of the biotechnol

Gabelli Funds LLC boosted its position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 38.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 643,859 shares of the biotechnology company's stock after buying an additi

Capital International Investors cut its stake in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 70.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 253,495 shares of the biotechnology comp

Cerevel Therapeutics (NASDAQ:CERE) Sees Large Volume Increase

SG Americas Securities LLC lowered its stake in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 80.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,833 shares of th

Cerevel Therapeutics (NASDAQ:CERE) Reaches New 1-Year High at $43.61

Chicago Capital Management LLC raised its position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 192.1% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 39,437 shares of the biotechnology company's stock after purc

Entropy Technologies LP bought a new stake in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 16,131 shares of the biotechnology company's stock, v

Tokio Marine Asset Management Co. Ltd. bought a new position in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 387,800 shares of the biotec

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Get Free Report) Director N Anthony Coles sold 25,000 shares of the company's stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $41.18, for a total value of $1,029,500.00. Following the sale, the director now owns 25,928 shares in the company, valued at approximately $1,067,715.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Cerevel Therapeutics (NASDAQ:CERE) Sees Large Volume Increase

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders bought 7,125 call options on the company. This is an increase of approximately 399% compared to the average volume of 1,428 call options.

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Get Free Report) was the target of a large drop in short interest in June. As of June 15th, there was short interest totalling 6,360,000 shares, a drop of 12.9% from the May 31st total of 7,300,000 shares. Approximately 7.3% of the company's stock are sold short. Based on an average trading volume of 1,250,000 shares, the short-interest ratio is currently 5.1 days.

Vanguard Group Inc. increased its position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 15.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,374,970 shares of the biotechnol

Goldman Sachs Group Inc. increased its holdings in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 64.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 532,757 shares of the

Perceptive Advisors LLC lifted its position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 8.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,965,193 shares of the biotechnology company's stock after

Governors Lane LP acquired a new position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 364,400 shares of the biotechnology company's stock, valued at approximately $15,451

Twin Securities Inc. acquired a new stake in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 232,705 shares of the biotechnology company's stock, valued at

Avidity Partners Management LP trimmed its position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 56.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 276,888 shares of the biotechnology company's stock after selling 366,112 shares du

Avoro Capital Advisors LLC boosted its stake in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 690.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,555,555 shares of the biotechnology comp